	US 12,486,504 B2
	Drug delivery composition, method for producing same and use thereof
Hirofumi Yamamoto, Osaka (JP); Masaki Mori, Atsugi (JP); Shuji Akai, Nishinomiya (JP); and Xin Wu, Shanghai (CN)
Assigned to Hirofumi Yamamoto, Osaka (JP)
Appl. No. 18/262,131
Filed by Hirofumi Yamamoto, Osaka (JP)
PCT Filed Jan. 18, 2022, PCT No. PCT/JP2022/001541 § 371(c)(1), (2) Date Jul. 19, 2023, PCT Pub. No. WO2022/158440, PCT Pub. Date Jul. 28, 2022.
Claims priority of application No. 2021-006747 (JP), filed on Jan. 19, 2021.
Prior Publication US 2024/0084299 A1, Mar. 14, 2024
Int. Cl. C12N 15/113 (2010.01); A61K 9/14 (2006.01); A61K 31/7105 (2006.01); A61P 35/00 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 9/143 (2013.01); A61K 9/146 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01)]

18 Claims

1. A composition comprising carbonate apatite particles loaded with a drug, wherein the carbonate apatite particles have an average particle size of larger than 500 nm and not more than 1000 nm, wherein the carbonate apatite particles are primary particles that are formed in the presence of a polyethylene glycol (PEG) derivative having one or more carboxylic acids or derivatives thereof or salts thereof at the ends thereof, whereby the PEG derivative is taken up in the primary particles.